Updated Jan 09, 2021 | 13:30 IST
Bharat Biotech says its intranasal vaccine candidate against COVID-19 has demonstrated unprecedented levels of protection in mice studies. What you need to know about Bharat Biotech’s intranasal COVID-19 vaccine BBV154 | Photo Credit: iStock Images
Key Highlights
Bharat Biotech to start phase 1 trials of its intranasal vaccine for COVID-19 in February-March
The nasal route has excellent potential for vaccination due to the organized immune systems of the nasal mucosa
The company owns the right to distribute the intranasal vaccine for COVID-19 in all markets except USA, Japan and Europe
Hyderabad: Bharat Biotech on Friday announced that it will begin the phase1 clinical trials of its new intranasal vaccine for the novel coronavirus (SARS-CoV-2) in February-March this year. The development came days after the Hyderabad-based firm received the Drugs Controller General of India’s (DCGI) nod for its COVID
Bharat Biotech to start Phase-1 trials for its second COVID-19 vaccine in Feb-March businessinsider.in - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from businessinsider.in Daily Mail and Mail on Sunday newspapers.
Updated Jan 08, 2021 | 15:11 IST
Bharat Biotech has said Phase-1 clinical trials of its new intranasal antidote for the killer virus will begin during February-March this year. Representational image | Photo Credit: PTI
New Delhi: The Bharat Biotech International Limited sent an application to the Drugs Controller General of India (DCGI) for conducting the phase 1 trials of an intranasal vaccine against the Covid-19 vaccine, a government official said on Friday.
The matter is yet to be taken up, the government official added. The company has said Phase-1 clinical trials of its new intranasal antidote for the killer virus will begin during February-March this year.